Designing therapeutics is a process with many challenges. Even if the first hurdle—
designing a drug that modulates the action of a particular biological target in vitro—is …

Dendrimers are discrete nanostructures/nanoparticles with 'onion skin‐like'branched layers.
Beginning with a core, these nanostructures grow in concentric layers to produce stepwise …

Dendrimers offer well-defined nanoarchitectures with spherical shape, high degree of
molecular uniformity, and multiple surface functionalities. Such unique structural properties …

Alzheimer's disease (AD) is a complex degenerative disease of the central nervous system
that is clinically characterized by a progressive decline in memory and cognitive function …

Neurotherapeutics for the treatment of central nervous system (CNS) disorders must
overcome challenges relating to the blood-brain barrier (BBB), brain tissue penetration, and …

Brain-related disorders have outmatched cancer and cardiovascular diseases worldwide as
the leading cause of morbidity and mortality. The lack of effective therapies and the relatively …

Alzheimer's disease (AD) is the most prevalent form of dementia. It affects more than 30
million people worldwide and costs over US $1.3 trillion annually. AD is characterized by the …

Poor transport of neuropharmaceutics through central nervous system (CNS) barriers limits
the development of effective treatments for CNS disorders. We present the facile synthesis of …

In this study, we used density functional theory (DFT) to predict polymer-drug interactions,
and then evaluated the ability of poly (vinyl pyrrolidone)(PVP) to inhibit crystallization of …

To address current complex health problems, there has been an increasing demand for
smart nanocarriers that could perform multiple complimentary biological tasks with high …